KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Return on Equity (2016 - 2025)

Pacific Biosciences Of California has reported Return on Equity over the past 15 years, most recently at 26.37% for Q4 2025.

  • Quarterly results put Return on Equity at 26.37% for Q4 2025, down 2572.0% from a year ago — trailing twelve months through Dec 2025 was 26.37% (down 2572.0% YoY), and the annual figure for FY2025 was 2.13%, down 162.0%.
  • Return on Equity for Q4 2025 was 26.37% at Pacific Biosciences Of California, down from 10.32% in the prior quarter.
  • Over the last five years, Return on Equity for PACB hit a ceiling of 0.03% in Q1 2021 and a floor of 26.37% in Q4 2025.
  • Median Return on Equity over the past 5 years was 0.49% (2023), compared with a mean of 2.88%.
  • Biggest five-year swings in Return on Equity: soared 195bps in 2021 and later crashed -2572bps in 2025.
  • Pacific Biosciences Of California's Return on Equity stood at 0.09% in 2021, then plummeted by -460bps to 0.53% in 2022, then grew by 21bps to 0.42% in 2023, then plummeted by -54bps to 0.65% in 2024, then crashed by -3984bps to 26.37% in 2025.
  • The last three reported values for Return on Equity were 26.37% (Q4 2025), 10.32% (Q3 2025), and 6.87% (Q2 2025) per Business Quant data.